OTUD7B Antibody

What is OTUD7B and why is it important for immunological research?

OTUD7B is an 843 amino acid protein that functions as a deubiquitinase, primarily localized in the nucleus and cytoplasm. Its significance lies in its ability to hydrolyze both branched and linear forms of polyubiquitin, particularly deubiquitinating Lys-48- and Lys-63-linked polyubiquitin chains. This activity is vital for regulating inflammatory responses within cells by modulating the ubiquitination status of target proteins . Additionally, OTUD7B plays a crucial role in T cell activation by acting as a positive regulator of TCR-proximal signaling through deubiquitinating Zap70 . For immunologists, OTUD7B represents an important regulatory node in inflammation and adaptive immunity, making its study valuable for understanding immune system dynamics and potential therapeutic interventions.

What detection methods can be used with OTUD7B antibody?

OTUD7B antibody can be utilized across multiple experimental platforms. The monoclonal antibody (such as H-4) has been validated for:

• Western blotting (WB) - For protein expression quantification

• Immunoprecipitation (IP) - For protein-protein interaction studies

• Immunofluorescence (IF) - For subcellular localization visualization

• Enzyme-linked immunosorbent assay (ELISA) - For quantitative detection

For optimal results in Western blotting, researchers should use recommended dilutions (typically 1:500-1:1000) and validate specificity using appropriate positive and negative controls. When performing immunofluorescence, a fixation optimization protocol is recommended as OTUD7B exhibits both nuclear and cytoplasmic localization patterns depending on cellular context and activation state.

What species reactivity is available for OTUD7B antibodies?

Commercial OTUD7B antibodies like the H-4 monoclonal antibody demonstrate cross-reactivity across multiple species, specifically detecting OTUD7B protein of mouse, rat, and human origin . This cross-species reactivity makes these antibodies versatile tools for comparative studies across different model organisms. Researchers should note that while the primary sequence homology supports this cross-reactivity, epitope accessibility may vary between species depending on protein folding and post-translational modifications, potentially affecting detection sensitivity.

How can OTUD7B antibody be used to investigate T cell activation mechanisms?

OTUD7B plays a critical role in T cell activation through its deubiquitinating activity on Zap70, a key molecule in TCR-proximal signaling . To investigate this mechanism:

• Experimental approach: Use OTUD7B antibody in conjunction with phospho-specific antibodies against TCR signaling components (e.g., Zap70, LAT, SLP-76) in Western blotting after T cell stimulation.

• Co-immunoprecipitation protocol:

  • Lyse 10^7 stimulated T cells in NP-40 lysis buffer

  • Pre-clear with protein G beads

  • Immunoprecipitate with OTUD7B antibody overnight

  • Analyze precipitates for Zap70 and other signaling molecules

• Functional verification: Compare TCR-induced calcium flux, cytokine production, and proliferation between OTUD7B-sufficient and OTUD7B-deficient T cells.

Research has demonstrated that OTUD7B deficiency results in reduced frequency of memory-like T cells in older mice and compromised T cell responses to Listeria monocytogenes infection, confirming its physiological importance in T cell function .

What are the considerations for using OTUD7B antibody in cancer research studies?

OTUD7B is highly expressed in lung squamous carcinoma and adenocarcinoma, correlating with poor prognosis . When designing cancer research studies using OTUD7B antibody, consider:

• Tissue microarray analysis: For comparing OTUD7B expression between tumor and adjacent normal tissues, use optimized immunohistochemical protocols with validated antibody dilutions.

• Signal pathway investigation: OTUD7B enhances EGF-induced Akt signal transduction, promoting cancer cell proliferation. Design experiments to examine:

  • Phosphorylation status of Akt (S473)

  • Activation of downstream effectors (p70S6K)

  • Correlation with VEGF expression

• Functional studies: Incorporate OTUD7B knockdown/overexpression in cancer cell lines followed by:

  • Proliferation assays (MTT)

  • Colony formation assays

  • Migration and invasion assays

  • VEGF ELISA

These approaches can help elucidate OTUD7B's role in cancer progression through the Akt/VEGF signaling pathway.

How can researchers distinguish between different OTUD7B isoforms using antibodies?

When investigating OTUD7B isoforms, researchers should consider:

• Epitope mapping: Determine which domain of OTUD7B the antibody recognizes (OTU domain, zinc finger domain, or TRAF-binding domain) .

• Isoform-specific detection: Use antibodies targeting unique regions of specific isoforms in combination with techniques like:

  • High-resolution SDS-PAGE to separate closely migrating isoforms

  • 2D gel electrophoresis for distinguishing post-translationally modified forms

  • Mass spectrometry for definitive isoform identification

• Validation approaches:

  • Recombinant expression of individual isoforms as positive controls

  • siRNA knockdown targeting specific isoform-encoding transcripts

  • CRISPR-mediated tagging of endogenous isoforms

This multi-faceted approach allows researchers to accurately identify which OTUD7B isoform is functioning in their biological system of interest.

What are the optimal conditions for immunoprecipitation with OTUD7B antibody?

For successful immunoprecipitation of OTUD7B and its interacting partners:

• Buffer composition: Use a lysis buffer containing:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40 or 0.5% Triton X-100

  • 1 mM EDTA

  • Protease inhibitor cocktail

  • Deubiquitinase inhibitors (e.g., N-ethylmaleimide)

• Protocol optimization:

  • Pre-clear lysates with protein G beads (1 hour at 4°C)

  • Incubate with OTUD7B antibody (2-5 μg per mg of total protein) overnight at 4°C

  • Add protein G beads for 2-4 hours

  • Wash 4-5 times with lysis buffer containing reduced detergent (0.1-0.25%)

  • Elute with SDS sample buffer or acidic glycine buffer

• Validation controls:

  • IgG control to assess non-specific binding

  • Input sample (5-10%) to confirm target protein presence

  • Reciprocal IP with known interaction partners

This approach maximizes specific enrichment of OTUD7B and its physiological binding partners while minimizing background.

How can researchers overcome non-specific binding issues with OTUD7B antibody in immunohistochemistry?

When performing immunohistochemistry with OTUD7B antibody, consider these strategies to minimize non-specific binding:

• Optimization steps:

  • Test multiple antibody dilutions (1:100 to 1:1000)

  • Compare different antigen retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Extend blocking time (2-3 hours with 5% normal serum)

  • Include 0.1-0.3% Triton X-100 in blocking buffer for better antibody penetration

• Validation approaches:

  • Use tissue from OTUD7B knockout models as negative controls

  • Perform peptide competition assays to confirm specificity

  • Compare staining patterns with multiple antibodies targeting different OTUD7B epitopes

• Signal enhancement without increased background:

  • Use amplification systems like tyramide signal amplification

  • Employ polymer-based detection systems

  • Consider overnight primary antibody incubation at 4°C

These techniques will help researchers achieve specific OTUD7B staining in tissue samples while minimizing background that could confound interpretation.

What is the recommended protocol for analyzing OTUD7B's role in deubiquitinating target proteins?

To investigate OTUD7B's deubiquitinating activity on specific target proteins:

• In vitro deubiquitination assay:

  • Immunoprecipitate the target protein under denaturing conditions

  • Incubate with recombinant OTUD7B protein

  • Analyze ubiquitination status by Western blotting with ubiquitin antibodies

• Cell-based ubiquitination analysis:

  • Transfect cells with HA-ubiquitin and OTUD7B expression constructs

  • Treat with proteasome inhibitors (MG132, 10 μM, 4-6 hours)

  • Perform IP under denaturing conditions (1% SDS, 95°C, 5 min)

  • Western blot with anti-HA antibody to detect ubiquitinated species

• Chain-specific ubiquitination analysis:

  • Use ubiquitin mutants or chain-specific antibodies to determine if OTUD7B preferentially cleaves K48-, K63-, or other linkage types

  • Compare effects on target protein stability and function

This comprehensive approach allows researchers to definitively characterize OTUD7B's deubiquitinating activity and its functional consequences on specific target proteins.

How can OTUD7B antibody be used in studying inflammatory disease mechanisms?

OTUD7B plays a crucial role in regulating inflammatory responses by participating in a negative feedback loop in pro-inflammatory signaling that suppresses NFκB activity . To study its role in inflammatory diseases:

• Tissue expression analysis:

  • Compare OTUD7B levels in inflamed versus normal tissues using immunohistochemistry

  • Correlate expression with inflammatory markers and disease severity scores

• Cell-specific mechanisms:

  • Use flow cytometry with OTUD7B antibody to assess expression in different immune cell populations

  • Combine with phospho-flow to correlate OTUD7B levels with NFκB and MAPK activation states

• Intervention studies:

  • Monitor OTUD7B expression changes following anti-inflammatory treatments

  • Use gene editing to modulate OTUD7B levels and assess impact on inflammatory responses

The role of OTUD7B in inflammation is particularly relevant as studies have shown that Otud7b deficiency ameliorates pathogenesis of T cell-dependent autoimmunity such as experimental autoimmune encephalomyelitis (EAE) , suggesting its potential as a therapeutic target.

What approaches can be used to study the interaction between OTUD7B and the Akt/VEGF signaling pathway in cancer?

OTUD7B has been shown to promote lung cancer cell proliferation and metastasis via the Akt/VEGF signal pathway . To investigate this interaction:

• Expression correlation analysis:

  • Perform immunohistochemical staining for OTUD7B and VEGF in tumor samples

  • Calculate correlation coefficients between expression levels

  • Compare with clinical outcomes data

• Signaling pathway dissection:

  • Conduct Western blot analysis for phosphorylated Akt (S473) and downstream targets after OTUD7B manipulation

  • Measure VEGF production using ELISA in control versus OTUD7B-overexpressing or OTUD7B-depleted cells

  • Assess angiogenic potential using tube formation assays with conditioned media

• Mechanistic studies:

  • Identify potential direct interactions between OTUD7B and Akt pathway components using proximity ligation assays

  • Determine if OTUD7B deubiquitinates specific components of the Akt pathway

  • Evaluate effects of OTUD7B on Akt membrane localization and activation

This integrated approach can help establish the precise mechanism by which OTUD7B influences cancer progression through the Akt/VEGF axis.

How can researchers integrate OTUD7B antibody-based assays with genomic and proteomic approaches?

Modern research benefits from multi-omics integration. For OTUD7B studies:

• Chromatin immunoprecipitation sequencing (ChIP-seq):

  • Use OTUD7B antibody for ChIP if OTUD7B functions as a transcriptional regulator

  • Combine with RNA-seq to correlate binding sites with gene expression changes

  • Identify transcription factors that co-occupy regulatory regions with OTUD7B

• Proximity-dependent biotinylation (BioID or TurboID):

  • Generate OTUD7B-BioID fusion constructs

  • Identify proximal proteins using streptavidin pulldown and mass spectrometry

  • Validate key interactions with co-immunoprecipitation using OTUD7B antibody

• Post-translational modification mapping:

  • Immunoprecipitate OTUD7B under various cellular conditions

  • Perform mass spectrometry to identify phosphorylation, ubiquitination, or other modifications

  • Correlate modifications with functional changes in OTUD7B activity

This integrated approach provides a systems-level understanding of OTUD7B function within cellular networks and identifies key nodes that could be targeted therapeutically.

What are the emerging applications of OTUD7B antibody in precision medicine research?

OTUD7B antibody has significant potential in precision medicine applications:

• Biomarker development:

  • OTUD7B is highly expressed in lung squamous carcinoma and adenocarcinoma, correlating with worse prognosis

  • Standardized immunohistochemical protocols could enable OTUD7B as a prognostic biomarker

  • Combined assessment with other markers may improve patient stratification

• Therapeutic target validation:

  • OTUD7B antibody can help validate this deubiquitinase as a druggable target

  • Monitor changes in OTUD7B expression and activity during disease progression

  • Assess OTUD7B inhibitor efficacy in preclinical models

• Patient selection strategies:

  • Identify patient subgroups with high OTUD7B expression who might benefit from targeted therapies

  • Develop companion diagnostic approaches using validated OTUD7B antibodies

These applications highlight the translational potential of basic research findings on OTUD7B function in cancer and inflammatory diseases.

What methodological improvements are needed for studying OTUD7B in different cellular compartments?

Current limitations and potential solutions include:

• Subcellular fractionation refinements:

  • Develop improved protocols to separate nuclear, cytoplasmic, and membrane-bound OTUD7B pools

  • Use antibodies targeting different OTUD7B domains to determine if truncated forms localize differently

  • Employ super-resolution microscopy to visualize OTUD7B at specific subcellular structures

• Live cell imaging approaches:

  • Generate validated fluorescent protein-tagged OTUD7B constructs that maintain function

  • Develop anti-OTUD7B nanobodies for live cell imaging applications

  • Implement optogenetic tools to manipulate OTUD7B activity in specific compartments

• Stimulus-specific trafficking studies:

  • Track OTUD7B redistribution following immune receptor engagement

  • Monitor trafficking in response to stress signals or cellular damage

  • Correlate localization changes with functional outcomes

These methodological improvements would significantly advance our understanding of how OTUD7B's subcellular localization influences its diverse functions.

How can conflicting results in OTUD7B research be reconciled through improved antibody validation?

The field has observed some contradictory findings regarding OTUD7B function, potentially due to antibody specificity issues:

• Comprehensive validation strategy:

  • Test antibodies on tissues/cells from OTUD7B knockout models

  • Conduct epitope mapping to identify precisely what region each antibody recognizes

  • Perform side-by-side comparisons of multiple antibodies on the same samples

• Standardized reporting:

  • Document detailed antibody information (clone, lot, dilution, incubation conditions)

  • Share raw data and unprocessed images to allow independent assessment

  • Report negative results to highlight potential context-dependent functions

• Functional correlation:

  • Combine antibody-based detection with functional readouts

  • Correlate protein levels with enzymatic activity measurements

  • Develop activity-based probes that detect only functionally active OTUD7B